Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025

Pfizer, Inc. (NYSE: PFE) is back in focus on December 5, 2025, as investors weigh a near‑7% dividend yield, fresh analyst commentary, a major obesity‑drug acquisition and a slate of upcoming guidance that will shape expectations for 2026.

Below is a detailed, news‑driven look at Pfizer stock today, including the latest price action, current Wall Street forecasts, and the biggest opportunities and risks now dominating the conversation.

Pfizer stock price today: where things stand

As of late trading on December 5, 2025, Pfizer shares are:

Around $26 per share (about $25.99 intraday), up roughly 1% on the day.
Within a 52‑week range of $20.92 to $27.69, leaving the stock ~24% above its April low and ~6% below its October high. ^[1]
Valued at about $146 billion in market capitalization. ^[2]
Trading at a mid‑teens P/E multiple (around 14–15x trailing earnings), cheaper than the broader S&P 500 on most metrics. ^[3]
Offering a dividend yield near 7%, based on an annualized $1.72 per share payout (about $0.43 quarterly), implying a yield of ~6.7–7.1% depending on the exact price snapshot used. ^[4]

Volatility is relatively low: one recent analysis pegs Pfizer’s rolling one‑year beta at just 0.59, reinforcing its status as a defensive, low‑volatility name. ^[5]

At the same time, long‑term performance has been disappointing. Over the past five years, Pfizer shares are down about 36%, and more than 50% below their pandemic‑era peak in late 2021, despite the hefty dividend. ^[6]

Fresh headlines on December 5, 2025

Several new pieces of coverage dropped today that shape how investors are thinking about Pfizer stock right now.

1. Motley Fool: “2 Headwinds Facing Pfizer Stock Going Into 2026”

A widely shared column published this morning highlights two major headwinds as Pfizer approaches 2026: ^[7]

Stricter COVID‑19 vaccine rules
- The article notes that the FDA has tightened eligibility for COVID boosters, focusing on high‑risk groups (older adults, the immunocompromised and others with severe risk factors).
- There is also discussion of more stringent standards for approving updated vaccines each year, potentially raising the bar for products like Comirnaty.
A looming wave of patent cliffs
- The author points to patent expirations beginning in 2026, including:
  - Xeljanz (an immunosuppressant whose sales are already declining),
  - Prevnar 13 within the broader pneumococcal vaccine franchise, and
  - Eventually, Eliquis, Pfizer’s best‑selling anticoagulant.
- Generic competition could pressure revenue even if some of these drugs are no longer major growth drivers.

Despite this, the piece emphasizes that Pfizer has rebuilt its pipeline and highlights candidates such as the oncology program PF‑4404 (aimed at competing with Merck’s Keytruda) along with new flu and weight‑management assets. It concludes that long‑term prospects are still attractive for patient, income‑focused investors thanks in part to Pfizer’s ~6.7% dividend yield. ^[8]

2. StockStory/Finviz: Pfizer flagged as a “low‑volatility stock with warning signs”

A new StockStory analysis (hosted on Finviz) groups Pfizer among “3 Low‑Volatility Stocks with Warning Signs”. ^[9]

Key concerns cited:

Core business underperformance: Organic revenue has disappointed over the past two years, suggesting Pfizer may need acquisitions (rather than internal growth) to move the needle.
Free‑cash‑flow pressure: A 26.5‑percentage‑point decline in free‑cash‑flow margin over five years signals heavier investment and weaker cash efficiency.
Eroding returns on capital: The report argues that Pfizer’s traditional profit engines are “aging,” leading to less attractive incremental returns.

Even so, the article notes that at about $25.7 per share, Pfizer trades around 8.6x forward earnings, a valuation that many would consider modest for a large, profitable pharma company.

3. Options market: “Smart money is betting big in PFE options”

A midday report from Benzinga highlights unusual options activity in Pfizer today. ^[10]

The article identifies 20 large options trades (calls and puts) in recent weeks.
Approximately 65% of this flow is classified as bearish, 35% bullish.
The implied price window based on strikes and open interest runs from roughly $20 to $35 over the coming months.
At the time of the report, shares were trading around $25.91, with the author noting that RSI readings suggest the stock may be approaching overbought territory.
The same piece notes two recent analyst moves:
- Citigroup reinstated coverage at Neutral with a $26 target,
- Guggenheim maintained a Buy / Strong Buy‑style rating with a $35 target. ^[11]

Overall, the options market appears actively engaged but cautiously skeptical, with traders positioning for a fairly wide trading range rather than a one‑sided breakout.

4. Institutional moves: Baird and Amundi trim their stakes

Two new 13F‑driven news alerts published today highlight changes in institutional ownership: ^[12]

Baird Financial Group
- Reduced its Pfizer position by 406,942 shares in Q2, a cut of about 14.5%, leaving it with ~2.39 million shares worth roughly $58 million at the time of filing.
Amundi (in a separate MarketBeat alert) also reported lower Pfizer holdings, underscoring some institutional profit‑taking after the stock’s rebound from its April lows.

Even after these reductions, around 68% of Pfizer’s shares are still in institutional hands, according to MarketBeat, underscoring its status as a core blue‑chip holding. ^[13]

These filings also reiterate that:

Pfizer’s 52‑week low is $20.92 and high is $27.69.
The company carries a debt‑to‑equity ratio of ~0.62 and maintains current and quick ratios around 1.28 and 0.97, respectively — not pristine, but generally comfortable for a large pharma. ^[14]

Fundamentals: what the latest earnings tell us

Full‑year 2024: strong non‑COVID growth, reset after the boom

Pfizer’s full‑year 2024 results, released in February 2025, help explain where the company is in its post‑pandemic reset: ^[15]

Revenue: $63.6 billion, up 7% year‑over‑year.
Non‑COVID products: Revenue up 12% operationally, showing that the base portfolio is growing even as COVID sales normalize.
Adjusted diluted EPS:$3.11, up 69% from 2023.
Management reaffirmed 2025 guidance at that time:
- Revenue: $61–64 billion.
- Adjusted EPS:$2.80–$3.00.

The company also delivered about $4 billion of net cost savings under a cost‑realignment program and increased its target to $4.5 billion by the end of 2025. ^[16]

Q3 2025: non‑COVID portfolio grows, EPS guidance raised

On November 4, 2025, Pfizer reported Q3 2025 results: ^[17]

Revenue: $16.7 billion, down 6% reported and 7% operationally vs. Q3 2024.
- However, non‑COVID revenues grew 4% operationally, driven by oncology and other key brands.
Adjusted diluted EPS:$0.87, down from $1.06 a year earlier but ahead of analyst expectations (around $0.79–0.87 depending on source). ^[18]
Nine‑month 2025 revenue: $45.0 billion, down about 2% year‑over‑year, reflecting declining COVID sales but solid performance elsewhere. ^[19]

Crucially, Pfizer:

Reaffirmed 2025 revenue guidance of $61–64 billion, and
Raised and narrowed 2025 adjusted EPS guidance to $3.00–$3.15 (from $2.90–$3.10), citing better execution, cost savings and a lower effective tax rate. ^[20]

The company expects to deliver about $7.2 billion in net cost savings by 2027, which should support margin expansion if revenue holds up. ^[21]

Consensus forecasts: flat revenue, slowly rising EPS

Independent aggregators of analyst estimates paint a picture of flattish sales but modest earnings growth: ^[22]

ValueInvesting.io estimates:
- Revenue this year: ~$63.5 billion, essentially flat vs. the prior year.
- Revenue next year: ~$63.1 billion (slight decline).
- EPS this year: about $3.13, up sharply from $1.41.
- EPS next year: ~$3.23, implying low single‑digit growth.

Investing.com’s Q3 coverage also notes that Pfizer beat EPS expectations (reporting $0.87) while revenue slightly missed, and that non‑COVID products showed 4% operational growth. ^[23]

Taken together, the fundamentals suggest:

Pfizer is successfully stabilizing earnings after the COVID boom,
Overall top‑line growth is limited for now, and
The margin story and capital allocation (dividends, cost cuts, M&A) are central to the bullish case.

Strategy pivot: obesity and oncology at the center

Metsera: Pfizer’s $10 billion obesity bet

Pfizer has moved aggressively to re‑enter the obesity and cardiometabolic market after shutting down its own oral GLP‑1 program. The key step: acquiring Metsera, a clinical‑stage obesity‑drug developer, in a deal worth up to $10 billion. ^[24]

Key details:

Pfizer agreed to pay $65.60 per share in cash, plus a contingent value right (CVR) of up to $20.65 per share tied to clinical and regulatory milestones.
The transaction values Metsera at about $7 billion upfront, with up to $10 billion total potential consideration.
Metsera’s lead candidate, MET‑097i, is a once‑monthly GLP‑1 injection that achieved up to 14.1% weight loss in mid‑stage trials and is moving toward late‑stage development. ^[25]
The obesity‑drug market is expected to reach $100–150 billion over the next decade, dominated today by Novo Nordisk and Eli Lilly. Pfizer is essentially paying to buy its way back into that race. ^[26]

Pfizer completed the acquisition in mid‑November, and Metsera is now a wholly owned subsidiary. Management frames this as a “deliberate investment in the future of medicine” and a key pillar of the company’s internal medicine franchise. ^[27]

Oncology: from Seagen to future blockbusters

Oncology already represents roughly a quarter of Pfizer’s revenue, and multiple sources expect it to be the primary growth driver through 2030. ^[28]

Pfizer’s Seagen acquisition, closed earlier, brought in a portfolio of antibody‑drug conjugates and other cancer therapies that management believes can support 8+ potential oncology blockbusters by 2030. ^[29]
Trefis notes that Pfizer’s last‑twelve‑months operating margin (~24.6%) and free‑cash‑flow margin (~16.5%) are healthy, and that the stock’s current valuation (P/E ~14.7 vs. an S&P 500 median of ~23.5) leaves room for multiple expansion if oncology and obesity franchises deliver. ^[30]

In short: Pfizer’s growth strategy now hinges on oncology innovation + obesity drugs + cost discipline to offset patent losses and COVID normalization.

Analyst ratings and price targets: what Wall Street expects

Despite the volatility of the last few years, analyst consensus on Pfizer is surprisingly consistent across platforms:

MarketBeat:
- 19 analysts tracked.
- Consensus rating: Hold (1 Sell, 12 Hold, 6 Buy/Strong Buy).
- Average 12‑month target:$28.39, implying about 9% upside from a price near $26. ^[31]
StockAnalysis:
- 10 analysts, consensus Hold.
- Average target:$28.30 (range $24–$35), implying roughly 9% upside. ^[32]
TickerNerd:
- 33 Wall Street analysts, overall consensus Neutral.
- Median target:$28.50 (range $24–$36.16).
- From a current price around $25.6, that’s about 11.5% implied upside. ^[33]
ValueInvesting.io:
- 33 analysts, consensus HOLD.
- Average target:$29.44 (range $24.24–$39.09), implying ~14% upside from roughly $25.3. ^[34]
Investing.com & 24/7 Wall St.:
- Note a consensus target in the high‑$28s (~$28.9) and an overall “Hold” view, with Pfizer seen as potentially undervalued relative to those targets and its dividend yield. ^[35]

Some outlier forecasts are more bullish:

Trefis fair‑value estimate:$32.23, implying ~25% upside from the mid‑$25s. ^[36]
24/7 Wall St.’s internal model:
- End‑2025 target:$33.60 (~31% upside from current).
- 2030 target:$34.08, suggesting low‑to‑mid‑30% upside over five years if their assumptions play out. ^[37]

Across these sources, the central message is:

Wall Street, on average, expects mid‑single to low‑double‑digit upside over 12 months, but sees Pfizer more as a steady income/value stock than a high‑growth story.

Market narrative: bulls vs. bears on Pfizer in late 2025

The bull case

Supportive voices (Trefis, some Seeking Alpha and value‑oriented managers) emphasize: ^[38]

Valuation: A P/E in the mid‑teens and a dividend yield near 7% look compelling versus the broader market.
Pipeline & M&A:
- Potential oncology blockbusters from the Seagen deal and internal R&D.
- The Metsera acquisition as a credible route into the explosive obesity‑drug market.
Cost savings and margin expansion: Billions in anticipated net savings by 2027 should support earnings even if revenues are roughly flat. ^[39]
Stabilizing share price: Several analyses note that Pfizer’s stock has “stabilized around $25” while institutions have been selectively adding, viewing it as a classic defensive dividend play with recovery potential. ^[40]

For this camp, Pfizer is not a hyper‑growth name, but a high‑yield, slowly improving blue chip whose long‑term total return could be attractive if execution on oncology and obesity goes well.

The bear (or cautious) case

More cautious analysis (Motley Fool’s headwinds piece, StockStory, some Zacks commentary) leans on the following: ^[41]

Patent cliffs & pricing pressure:
- Major products (Xeljanz, parts of the Prevnar franchise, Eliquis) will face generic competition over the next several years.
- The Inflation Reduction Act and Medicare price negotiations are already biting; one report notes an $825 million hit in Q2 2025 tied to Medicare Part D changes, highlighting the regulatory headwinds. ^[42]
COVID normalization: Revenue from Comirnaty and Paxlovid is now a fraction of peak levels and faces stricter regulatory guidance, limiting upside from booster waves. ^[43]
Mixed revenue trend: Overall revenue is basically flat to slightly down, with non‑COVID growth doing just enough to offset declines elsewhere.
Capital‑intensive strategy:
- Acquisitions like Seagen and Metsera are expensive.
- Free‑cash‑flow margins have fallen versus five years ago, and returns on capital are under pressure. ^[44]

StockStory goes as far as suggesting investors “steer clear” of Pfizer in favor of higher‑growth, better‑return alternatives, despite acknowledging its defensive qualities and low volatility. ^[45]

Activist angle: Starboard exits

In November, activist hedge fund Starboard Value disclosed that it had fully exited its Pfizer stake, selling roughly 8.5 million shares in Q3 after initially building a ~$1 billion position in late 2024. ^[46]

Starboard’s campaign pushed for changes to boost Pfizer’s share price, but the stock’s market value actually fell from about $162 billion to $142 billion during its involvement.
Commentators at Finimize frame the exit as a sign that “even well‑known activists can’t always engineer a quick fix when fundamentals are in flux”, suggesting that the big drivers for Pfizer going forward will be execution, not activism. ^[47]

Technical posture and sentiment snapshot

Without relying on charts, a few data points give a feel for how the market is positioned:

Price vs. range: At around $26, PFE trades closer to its 52‑week high than its low, but still well below its 2021 peak above $50. ^[48]
Low volatility: Beta readings in the 0.4–0.6 area and StockStory’s “low‑volatility” label underscore Pfizer’s role as a defensive, lower‑beta name. ^[49]
Options skew: Benzinga’s analysis of unusual options flow shows more bearish than bullish positioning (65% vs. 35%), but with both puts and calls active in a $20–$35 strike range — suggesting expectation of continued range‑bound trading with the potential for spikes on big news. ^[50]
Short‑term performance: 24/7 Wall St. notes that Pfizer gained about 3.7% in the past month and nearly 10% in the month before that, trimming but not erasing its ~4% year‑to‑date loss. ^[51]

Catalysts to watch in December 2025 and beyond

1. December 16, 2025 – 2026 guidance call

Pfizer has scheduled a December 16 analyst call to provide full‑year 2026 financial guidance, which is likely the next major catalyst for the stock. ^[52]

Investors will focus on:

2026 revenue and EPS ranges, especially how management frames:
- Obesity and oncology contributions,
- Patent‑cliff impacts, and
- Continuing cost‑savings.
Any updated commentary on Metsera, including timelines for late‑stage trials.
Capital allocation priorities for 2026 and beyond (dividends vs. debt reduction vs. buybacks).

A guidance range above current consensus (roughly flat revenue and low‑single‑digit EPS growth) would bolster the bullish case. A conservative outlook could reinforce the “Hold” consensus.

2. Metsera development updates

As Metsera moves through late‑stage trials, key milestones — phase 3 data, design details, regulatory interactions — will heavily influence how investors value Pfizer’s obesity ambitions. ^[53]

Positive data that confirms strong efficacy and a convenient once‑monthly dosing advantage over weekly competitors could materially change long‑term revenue expectations.

3. Ongoing regulatory and pricing developments

Investors will continue to watch:

The Inflation Reduction Act and Medicare negotiation process for additional price cuts. ^[54]
Any new US or EU policies on obesity drugs and oncology pricing, which could affect both Metsera and Seagen‑derived revenues.

What today’s picture means for Pfizer stock

Putting all of this together, Pfizer stock on December 5, 2025 looks like:

A high‑yield, relatively low‑volatility blue chip trading at a discount to the broader market on earnings,
With flat to modest growth expected near term,
And meaningful long‑term optionality tied to obesity and oncology — but also substantial headwinds from patent cliffs and pricing reforms.

In practical terms:

Income‑oriented investors will focus on the nearly 7% dividend yield, the company’s history of paying and growing dividends, and its large, diversified portfolio. ^[55]
Growth‑oriented investors will look closely at the Metsera pipeline, Seagen‑driven oncology opportunities, and whether 2026 guidance signals a clear path back to sustainable top‑line expansion. ^[56]
Risk‑aware investors will watch how the company navigates regulatory pressure, patent expirations, and capital‑intensive dealmaking, as highlighted by both cautious fundamental analyses and the mixed tone of options and activist activity. ^[57]

Important note

This article is informational and news‑oriented. It summarizes publicly available data, analyst reports and recent coverage as of December 5, 2025. It is not financial advice or a recommendation to buy, hold, or sell Pfizer or any other security. Always consider your own objectives, risk tolerance and, if needed, consult a licensed financial adviser before making investment decisions.

References

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks